Randomized controlled study investigating viral suppression and serological response following Pre-S1/Pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5134-5140

  Hoa, Pham Thi Le ^a,b   Huy, Nguyen Tien ^c   Thu, Le The ^d   Nga, Cao Ngoc ^a,b   Nakao, Kazuhiko ^c   Eguchi, Katsumi ^c   Chi, Nguyen Huu ^a,b   Hoang, Bui Huu ^a   Hirayama, Kenji ^c  

^a UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c NAGASAKI UNIVERSITY   (Japan)

^d CAN THO UNIVERSITY OF MEDICINE AND PHARMACY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; SCI B VAC; UNCLASSIFIED DRUG; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; TREATMENT OUTCOME;

EID: 71249096453     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00276-09     Document Type: Article

References (45)

1. Akbar, S. M., M. Abe, T. Masumoto, N. Horiike, and M. Onji. 1999. Mechanism of action of vaccine therapy in murine hepatitis B virus carriers: vaccine-induced activation of antigen presenting dendritic cells. J. Hepatol. 30:755-764.
2. Böcher, W. O., S. Herzog-Hauff, W. Herr, K. Heermann, G. Gerken, K. H. Meyer zum Buschenfelde, and H. F. Lohr. 1996. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin. Exp. Immunol. 105:52-58.
3. Bosch, F. X., J. Ribes, R. Cleries, and M. Diaz. 2005. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 9:191-211.
4. Brown, J. L., W. F. Carman, and H. C. Thomas. 1990. The hepatitis B virus. Baillieres Clin. Gastroenterol. 4:721-747.
5. Chu, C. J., M. Hussain, and A. S. Lok. 2002. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122:1756-1762. (Pubitemid 34651418)
6. Couillin, I., S. Pol, M. Mancini, F. Driss, C. Brechot, P. Tiollais, and M. L. Michel. 1999. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180:15-26.
7. de Franchis, R., A. Hadengue, G. Lau, D. Lavanchy, A. Lok, N. McIntyre, A. Mele, G. Paumgartner, A. Pietrangelo, J. Rodes, W. Rosenberg, and D. Valla. 2003. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version). J. Hepatol. 39(Suppl. 1):S3-S25.
8. Dusheiko, G., and N. Antonakopoulos. 2008. Current treatment of hepatitis B. Gut 57:105-124.
9. Fattovich, G., F. Bortolotti, and F. Donato. 2008. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48:335-352.
10. Gish, R. G. 2007. Improving outcomes for patients with chronic hepatitis B. Curr. Gastroenterol. Rep. 9:14-22.
11. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
12. Horiike, N., S. M. Fazle Akbar, K. Michitaka, K. Joukou, K. Yamamoto, N. Kojima, Y. Hiasa, M. Abe, and M. Onji. 2005. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J. Clin. Virol. 32:156-161.
13. Horiike, N., S. M. Fazle Akbar, T. Ninomiya, M. Abe, K. Michitaka, and M. Onji. 2002. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol. Res. 23:38-47.
14. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. 2006. Guidance for diagnosis and treatment of common infectious diseases, p. 54-59. Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
15. Hsu, H. Y., M. H. Chang, S. H. Liaw, Y. H. Ni, and H. L. Chen. 1999. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312-1317.
16. Hsu, Y. S., R. N. Chien, C. T. Yeh, I. S. Sheen, H. Y. Chiou, C. M. Chu, and Y. F. Liaw. 2002. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35:1522-1527. (Pubitemid 34966908)
17. Hui, C. K., and G. K. Lau. 2005. Advances in immunomodulating therapy of HBV infection. Int. J. Med. Sci. 2:24-29.
18. Ishikawa, T., and S. Kakumu. 2007. Combination therapy with lamivudine and HB vaccine on chronic hepatitis B. Hepatol. Res. 37:S62-S66.
19. Jung, M. C., U. Spengler, W. Schraut, R. Hoffmann, R. Zachoval, J. Eisenburg, D. Eichenlaub, G. Riethmuller, G. Paumgartner, H. W. Ziegler-Heitbrock, et al. 1991. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol. 13:310-317.
20. Kane, M. 1995. Global programme for control of hepatitis B infection. Vaccine 13(Suppl. 1):S47-S49.
21. Lada, O., Y. Benhamou, T. Poynard, and V. Thibault. 2006. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J. Virol. 80:2968-2975.
22. Lau, G. K., T. Piratvisuth, K. X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, M. W. Fried, W. C. Chow, S. W. Paik, W. Y. Chang, T. Berg, R. Flisiak, P. McCloud, and N. Pluck. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352:2682-2695.
23. Lavanchy, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11:97-107. (Pubitemid 38365759)
24. Lee, Y. S., D. J. Suh, Y. S. Lim, S. W. Jung, K. M. Kim, H. C. Lee, Y. H. Chung, Y. S. Lee, W. Yoo, and S. O. Kim. 2006. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43:1385-1391.
25. Liaw, Y. F., N. Leung, R. Guan, G. K. Lau, I. Merican, G. McCaughan, E. Gane, J. H. Kao, and M. Omata. 2005. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 25:472-489.
26. Locarnini, S. 2005. Molecular virology and the development of resistant mutants: implications for therapy. Semin. Liver Dis. 25(Suppl. 1):9-19.
27. Lok, A. S. 2005. The maze of treatments for hepatitis B. N. Engl. J. Med. 352:2743-2746.
28. Lok, A. S., and B. J. McMahon. 2007. Chronic hepatitis B. Hepatology 45:507-539.
29. Lok, A. S. F., and B. J. McMahon. 2001. Chronic hepatitis B. Hepatology 34:1225-1241.
30. Maddrey, W. C. 2001. Hepatitis B-an important public health issue. Clin. Lab. 47:51-55.
31. Margeridon, S., A. Lachaux, C. Trepo, F. Zoulim, and A. Kay. 2005. A quasi-monoclonal anti-HBs response can lead to immune escape of 'wildtype' hepatitis B virus. J. Gen. Virol. 86:1687-1693.
32. McMahon, B. J. 2004. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 24(Suppl. 1):17-21.
33. Montori, V. M., and G. H. Guyatt. 2001. Intention-to-treat principle. CMAJ 165:1339-1341.
34. Papatheodoridis, G. V., E. Dimou, A. Laras, V. Papadimitropoulos, and S. J. Hadziyannis. 2002. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36:219-226.
35. Papatheodoridis, G. V., S. Manolakopoulos, G. Dusheiko, and A. J. Archimandritis. 2008. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 8:167-178.
36. Phuong, N. T. M., B. Dai, and N. T. Chinh. 2004. Efficacy of lamivudine monotherapy and lamivudine combination with Hepa-B-vac for active chronic hepatitis B. Tap Chi Thong Tin Y Duoc (The national seminar on hepatobiliary diseases in HCM city) 2004:57-61.
37. Pol, S., F. Driss, M. L. Michel, B. Nalpas, P. Berthelot, and C. Brechot. 1994. Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342. (Pubitemid 24230322)
38. Pol, S., B. Nalpas, F. Driss, M. L. Michel, P. Tiollais, J. Denis, and C. Brecho. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34:917-921. (Pubitemid 32595193)
39. Sherman, M., V. Bain, J. P. Villeneuve, R. P. Myers, C. Cooper, S. Martin, and C. Lowe. 2004. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can. J. Gastroenterol. 18:715-728.
40. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
41. Vandepapelière, P., G. K. Lau, G. Leroux-Roels, Y. Horsmans, E. Gane, T. Tawandee, M. I. Merican, K. M. Win, C. Trepo, G. Cooksley, M. Wettendorff, and C. Ferrari. 2007. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585-8597.
42. Wen, Y. M., X. H. Wu, D. C. Hu, Q. P. Zhang, and S. Q. Guo. 1995. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575-1576.
43. Yap, I., R. Guan, and S. H. Chan. 1995. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J. Gastroenterol. Hepatol. 10:51-55.
44. Zheng, X., K. M. Weinberger, R. Gehrke, M. Isogawa, G. Hilken, T. Kemper, Y. Xu, D. Yang, W. Jilg, M. Roggendorf, and M. Lu. 2004. Mutant hepatitis B virus surface antigens (HBsAg) are immunogenic but may have a changed specificity. Virology 329:454-464.
45. Zuckerman, J. N., C. Sabin, F. M. Craig, A. Williams, and A. J. Zuckerman. 1997. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind doseresponse study. BMJ 314:329-333.